Ligand Pharmaceuticals (LGND) Prepaid Assets (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Prepaid Assets of $5.8 million for Q1 2026, little changed sequentially from $5.8 million in Q4 2025, and down 56.38% YoY from $13.3 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Prepaid Assets (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Prepaid Assets for 17 years, with the latest figure at $5.8 million in Q1 2026.
- Quarterly Prepaid Assets fell 56.38% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (down 56.38% YoY) and the FY2025 annual result came in at $5.8 million, down 34.31% from the prior year.
- Prepaid Assets steadied at $5.8 million in Q1 2026 per LGND's latest filing, from $5.8 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $19.7 million in Q3 2024 and troughed at $1.1 million in Q4 2022.
- A 5-year average of $6.7 million and a median of $5.8 million in 2026 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets sank 80.49% in 2023, then surged 841.39% in 2024.
- Over 5 years, Prepaid Assets stood at $1.1 million in 2022, then surged by 134.72% to $2.7 million in 2023, then surged by 231.43% to $8.8 million in 2024, then slumped by 34.31% to $5.8 million in 2025, then increased by 0.17% to $5.8 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $5.8 million, $5.8 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.19 Mn |
| Mar 31, 2026 | 5.80 Mn |
| Dec 31, 2025 | 5.79 Mn |
| Sep 30, 2025 | 6.99 Mn |
| Jun 30, 2025 | 4.82 Mn |
| Mar 31, 2025 | 13.29 Mn |
| Dec 31, 2024 | 8.81 Mn |
| Sep 30, 2024 | 19.74 Mn |
| Jun 30, 2024 | 7.12 Mn |
| Mar 31, 2024 | 7.31 Mn |
| Dec 31, 2023 | 2.66 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 2.77 Mn |
| Mar 31, 2023 | 2.33 Mn |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | 10.75 Mn |
| Jun 30, 2022 | 7.80 Mn |
| Mar 31, 2022 | 4.66 Mn |
| Dec 31, 2021 | 3.57 Mn |
| Sep 30, 2021 | 5.16 Mn |